StockData
ANI Pharmaceuticals Inc logo

ANI Pharmaceuticals Inc (ANIP) stock

ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$71.47+1.48 (+2.11%)

Close on Nov 18, 2026Market cap $1.64BP/E 15.2Yield –

ANI Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

ANI Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $978.38M, up 30.9% year over year. For fiscal 2025 it was $883.37M, up 43.8% from the year before. Over ten years it grew 27.7% a year on average. The highest annual figure on record is $883.37M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$883.37M+43.8%
FY2024Dec 31, 2024$614.38M+26.2%
FY2023Dec 31, 2023$486.82M+53.9%
FY2022Dec 31, 2022$316.39M+46.4%
FY2021Dec 31, 2021$216.14M+3.7%
FY2020Dec 31, 2020$208.48M+0.9%
FY2019Dec 31, 2019$206.55M+2.5%
FY2018Dec 31, 2018$201.58M+14.0%
FY2017Dec 31, 2017$176.84M+37.5%
FY2016Dec 31, 2016$128.62M+68.5%
FY2015Dec 31, 2015$76.32M+36.4%
FY2014Dec 31, 2014$55.97M+86.1%
FY2013Dec 31, 2013$30.08M+47.7%
FY2012Dec 31, 2012$20.37M+4581.3%
FY2011Dec 31, 2011$435.16K-82.4%
FY2010Dec 31, 2010$2.47M+96.7%
FY2009Dec 31, 2009$1.26M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$266.04M+25.9%
Q1 FY2026Mar 31, 2026$237.46M+20.5%
Q4 FY2025Dec 31, 2025$247.06M+29.6%
Q3 FY2025Sep 30, 2025$227.81M+53.6%
Q2 FY2025Jun 30, 2025$211.37M+53.1%
Q1 FY2025Mar 31, 2025$197.12M+43.4%
Q4 FY2024Dec 31, 2024$190.57M+44.8%
Q3 FY2024Sep 30, 2024$148.33M+12.5%
Q2 FY2024Jun 30, 2024$138.04M+18.4%
Q1 FY2024Mar 31, 2024$137.43M+28.7%
Q4 FY2023Dec 31, 2023$131.65M+39.7%
Q3 FY2023Sep 30, 2023$131.83M+57.3%
Q2 FY2023Jun 30, 2023$116.55M+57.8%
Q1 FY2023Mar 31, 2023$106.79M+65.6%
Q4 FY2022Dec 31, 2022$94.23M+54.7%
Q3 FY2022Sep 30, 2022$83.82M+61.0%
Q2 FY2022Jun 30, 2022$73.86M+51.9%
Q1 FY2022Mar 31, 2022$64.48M+18.3%
Q4 FY2021Dec 31, 2021$60.93M+6.4%
Q3 FY2021Sep 30, 2021$52.06M-1.7%
Q2 FY2021Jun 30, 2021$48.63M+0.3%
Q1 FY2021Mar 31, 2021$54.52M+9.5%
Q4 FY2020Dec 31, 2020$57.25M+19.4%
Q3 FY2020Sep 30, 2020$52.98M+3.2%
Q2 FY2020Jun 30, 2020$48.47M-10.8%
Q1 FY2020Mar 31, 2020$49.77M-5.9%
Q4 FY2019Dec 31, 2019$47.97M-16.0%
Q3 FY2019Sep 30, 2019$51.34M+1.3%
Q2 FY2019Jun 30, 2019$54.36M+15.0%
Q1 FY2019Mar 31, 2019$52.89M+13.8%
Q4 FY2018Dec 31, 2018$57.12M+20.8%
Q3 FY2018Sep 30, 2018$50.70M+5.3%
Q2 FY2018Jun 30, 2018$47.27M+5.6%
Q1 FY2018Mar 31, 2018$46.48M+26.9%
Q4 FY2017Dec 31, 2017$47.29M+23.8%
Q3 FY2017Sep 30, 2017$48.16M+25.0%
Q2 FY2017Jun 30, 2017$44.76M–
Q1 FY2017Mar 31, 2017$36.63M–
Q4 FY2016Dec 31, 2016$38.21M–
Q3 FY2016Sep 30, 2016$38.53M–

More ANI Pharmaceuticals figures

See a number that looks wrong?